CN109528762A - 一种亮氨酸血液透析浓缩液及其制备方法 - Google Patents
一种亮氨酸血液透析浓缩液及其制备方法 Download PDFInfo
- Publication number
- CN109528762A CN109528762A CN201811613342.5A CN201811613342A CN109528762A CN 109528762 A CN109528762 A CN 109528762A CN 201811613342 A CN201811613342 A CN 201811613342A CN 109528762 A CN109528762 A CN 109528762A
- Authority
- CN
- China
- Prior art keywords
- liquid
- haemodialysis
- concentration
- leucine
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 89
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 title claims abstract description 43
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 60
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 30
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 28
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 24
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000001110 calcium chloride Substances 0.000 claims abstract description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 15
- 239000011780 sodium chloride Substances 0.000 claims abstract description 15
- 239000001103 potassium chloride Substances 0.000 claims abstract description 14
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 238000000502 dialysis Methods 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 3
- 238000005660 chlorination reaction Methods 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- 229910052749 magnesium Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- YMUZAKCMWLUMBZ-UHFFFAOYSA-I [C+4].[Cl-].[K+].[Cl-].[Cl-].[Cl-].[Cl-] Chemical compound [C+4].[Cl-].[K+].[Cl-].[Cl-].[Cl-].[Cl-] YMUZAKCMWLUMBZ-UHFFFAOYSA-I 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种亮氨酸血液透析浓缩液，包括血液透析浓缩A液和血液透析浓缩B液:所述血液透析浓缩A液由以下物质组成：氯化钠、氯化钾、氯化钙、氯化镁、亮氨酸和水；所述血液透析浓缩B液由以下物质组成：碳酸氢钠和水。本发明提供一种亮氨酸血液透析浓缩液及其制备方法，该亮氨酸血液透析浓缩液生产过程对人友好，对眼鼻无刺激性。
Description
技术领域
本发明涉及血液透析浓缩液领域。更具体地说，本发明涉及一种亮氨酸血液透析浓缩液及其制备方法。
背景技术
血液透析(HD)是急慢性肾功能衰竭患者肾脏替代治疗方式之一。它通过将体内血液引流至体外，经一个由无数根空心纤维组成的透析器中，血液与含机体浓度相似的电解质溶液(透析液)在一根根空心纤维内外，通过弥散、浓度梯度和对流原理进行电解质平衡，带走体内的代谢废物、维持电解质和酸碱平衡；同时清除体内过多的水分，整个过程称为血液透析。现有的血液透析浓缩液的配方是用冰醋酸作为Ph调节剂，冰醋酸本身对人体没有益处，水溶液中呈弱酸性且蚀性强，对眼和鼻有刺激性作用，生产过程冰醋酸强烈的刺激性气味会让人极度不适。
发明内容
本发明的目的是提供一种亮氨酸血液透析浓缩液及其制备方法，该亮氨酸血液透析浓缩液生产过程对人友好，对眼鼻无刺激性。
为了实现根据本发明的这些目的和其它优点，提供了一种亮氨酸血液透析浓缩液，包括血液透析浓缩A液和血液透析浓缩B液:
所述血液透析浓缩A液由以下物质组成：氯化钠、氯化钾、氯化钙、氯化镁、亮氨酸和水；
所述血液透析浓缩B液由以下物质组成：碳酸氢钠和水。
优选的是，所述的一种亮氨酸血液透析浓缩液中，所述血液透析浓缩A液和所述血液透析浓缩B液的质量比为1:1-2。
优选的是，所述的一种亮氨酸血液透析浓缩液中，所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠200-220g/L、氯化钾4-6g/L、氯化钙6-8g/L、氯化镁2-4g/L和亮氨酸12-16g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为80-90g/L。
优选的是，所述的一种亮氨酸血液透析浓缩液中，所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠210.7g/L、氯化钾5.21g/L、氯化钙7.718g/L、氯化镁3.558g/L和亮氨酸13.77g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为84.01g/L。
一种上述亮氨酸血液透析浓缩液的制备方法，包括以下步骤：
S1、配置氯化钠浓度为200-220g/L、氯化钾浓度为4-6g/L、氯化钙浓度为6-8g/L、氯化镁浓度为2-4g/L和亮氨酸浓度为12-16g/L的血液透析浓缩A液，备用；
S2、配置碳酸氢钠浓度为80-90g/L的血液透析浓缩B液，备用；
S3、将血液透析浓缩A液、血液透析浓缩B液和透析用水混合均匀后，即制得所述亮氨酸血液透析浓缩液。
本发明的有益效果是：
1、本发明的亮氨酸血液透析浓缩液的生产过程不会使人产生不适感，解决现有的冰醋酸对眼和鼻的刺激性。
2、本发明的亮氨酸血液透析浓缩液中用亮氨酸代替了冰醋酸：亮氨酸与异亮氨酸和缬氨酸一起合作修复肌肉，控制血糖，并给身体组织提供能量。
本发明的其它优点、目标和特征将部分通过下面的说明体现，部分还将通过对本发明的研究和实践而为本领域的技术人员所理解。
具体实施方式
下面结合实施例对本发明做进一步的详细说明，以令本领域技术人员参照说明书文字能够据以实施。
<实施例1>
一种亮氨酸血液透析浓缩液，包括血液透析浓缩A液和血液透析浓缩B液:
所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠200g/L、氯化钾4g/L、氯化钙6g/L、氯化镁2g/L和亮氨酸12g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为80g/L。
一种上述亮氨酸血液透析浓缩液的制备方法，包括以下步骤：
S1、配置氯化钠浓度为200g/L、氯化钾浓度为4g/L、氯化钙浓度为6g/L、氯化镁浓度为2g/L和亮氨酸浓度为12g/L的血液透析浓缩A液，备用；
S2、配置碳酸氢钠浓度为80g/L的血液透析浓缩B液，备用；
S3、将血液透析浓缩A液、血液透析浓缩B液和透析用水混合均匀后，即制得所述亮氨酸血液透析浓缩液。
<实施例2>
一种亮氨酸血液透析浓缩液，包括血液透析浓缩A液和血液透析浓缩B液:
所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠210.7g/L、氯化钾5.21g/L、氯化钙7.718g/L、氯化镁3.558g/L和亮氨酸13.77g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为84.01g/L。
一种上述亮氨酸血液透析浓缩液的制备方法，包括以下步骤：
S1、配置氯化钠浓度为210.7g/L、氯化钾浓度为5.21g/L、氯化钙浓度为7.718g/L、氯化镁浓度为3.558g/L和亮氨酸浓度为13.77g/L的血液透析浓缩A液，备用；
S2、配置碳酸氢钠浓度为84.01g/L的血液透析浓缩B液，备用；
S3、将血液透析浓缩A液、血液透析浓缩B液和透析用水混合均匀后，即制得所述亮氨酸血液透析浓缩液。
<实施例3>
一种亮氨酸血液透析浓缩液，包括血液透析浓缩A液和血液透析浓缩B液:
所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠220g/L、氯化钾6g/L、氯化钙8g/L、氯化镁4g/L和亮氨酸16g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为90g/L。
一种上述亮氨酸血液透析浓缩液的制备方法，包括以下步骤：
S1、配置氯化钠浓度为220g/L、氯化钾浓度为6g/L、氯化钙浓度为8g/L、氯化镁浓度为4g/L和亮氨酸浓度为12g/L的血液透析浓缩A液，备用；
S2、配置碳酸氢钠浓度为90g/L的血液透析浓缩B液，备用；
S3、将血液透析浓缩A液、血液透析浓缩B液和透析用水混合均匀后，即制得所述亮氨酸血液透析浓缩液。
上述实施例中所使用的水均为透析用水，所涉及化验方法均为本领域常规的离子检验法。
尽管本发明的实施方案已公开如上，但其并不仅仅限于说明书和实施方式中所列运用，它完全可以被适用于各种适合本发明的领域，对于熟悉本领域的人员而言，可容易地实现另外的修改，因此在不背离权利要求及等同范围所限定的一般概念下，本发明并不限于特定的细节和这里示出与描述的实施例。
Claims (5)
1.一种亮氨酸血液透析浓缩液，包括血液透析浓缩A液和血液透析浓缩B液，其特征在于:
所述血液透析浓缩A液由以下物质组成：氯化钠、氯化钾、氯化钙、氯化镁、亮氨酸和水；
所述血液透析浓缩B液由以下物质组成：碳酸氢钠和水。
2.如权利要求1所述的一种亮氨酸血液透析浓缩液，其特征在于，所述血液透析浓缩A液和所述血液透析浓缩B液的质量比为1:1-2。
3.如权利要求1或2所述的一种亮氨酸血液透析浓缩液，其特征在于，所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠200-220g/L、氯化钾4-6g/L、氯化钙6-8g/L、氯化镁2-4g/L和亮氨酸12-16g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为80-90g/L。
4.如权利要求3所述的一种亮氨酸血液透析浓缩液，其特征在于，所述血液透析浓缩A液包括以下质量浓度的各组分：氯化钠210.7g/L、氯化钾5.219g/L、氯化钙7.718g/L、氯化镁3.558g/L和亮氨酸13.77g/L，所述血液透析浓缩B液中碳酸氢钠的质量浓度为84.01g/L。
5.一种如权利要求3所述的亮氨酸血液透析浓缩液的制备方法，其特征在于，包括以下步骤：
S1、配置氯化钠浓度为200-220g/L、氯化钾浓度为4-6g/L、氯化钙浓度为6-8g/L、氯化镁浓度为2-4g/L和亮氨酸浓度为12-16g/L的血液透析浓缩A液，备用；
S2、配置碳酸氢钠浓度为80-90g/L的血液透析浓缩B液，备用；
S3、将血液透析浓缩A液、血液透析浓缩B液和透析用水混合均匀后，即制得所述亮氨酸血液透析浓缩液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811613342.5A CN109528762A (zh) | 2018-12-27 | 2018-12-27 | 一种亮氨酸血液透析浓缩液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811613342.5A CN109528762A (zh) | 2018-12-27 | 2018-12-27 | 一种亮氨酸血液透析浓缩液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109528762A true CN109528762A (zh) | 2019-03-29 |
Family
ID=65856748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811613342.5A Pending CN109528762A (zh) | 2018-12-27 | 2018-12-27 | 一种亮氨酸血液透析浓缩液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109528762A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003095937A (ja) * | 2001-07-17 | 2003-04-03 | Otsuka Pharmaceut Factory Inc | 末梢静脈用輸液 |
| CN102370990A (zh) * | 2010-08-09 | 2012-03-14 | 俞黎黎 | 用苹果酸作为pH调节剂的血液净化用制剂及其制备方法和应用 |
| CN104208020A (zh) * | 2014-09-05 | 2014-12-17 | 河北一品制药有限公司 | 一种盐酸罗哌卡因注射液及其制备方法 |
-
2018
- 2018-12-27 CN CN201811613342.5A patent/CN109528762A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003095937A (ja) * | 2001-07-17 | 2003-04-03 | Otsuka Pharmaceut Factory Inc | 末梢静脈用輸液 |
| CN102370990A (zh) * | 2010-08-09 | 2012-03-14 | 俞黎黎 | 用苹果酸作为pH调节剂的血液净化用制剂及其制备方法和应用 |
| CN104208020A (zh) * | 2014-09-05 | 2014-12-17 | 河北一品制药有限公司 | 一种盐酸罗哌卡因注射液及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 骆小丽: "《女人这样做吃不胖、晒不黑、人不老 超值白金典藏版》", 31 July 2016 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henderson | The problem of peritoneal membrane area and permeability | |
| RU2311202C1 (ru) | Способ получения кислотного компонента для бикарбонатного гемодиализа | |
| JP2004331675A (ja) | 生化学的にバランスさせた腹膜透析溶液 | |
| Zanella et al. | Extracorporeal carbon dioxide removal through ventilation of acidified dialysate: an experimental study | |
| JP2018534117A (ja) | 体外での二酸化炭素除去のための方法 | |
| US20120035523A1 (en) | System for treatment of blood | |
| MacLaren et al. | Central extracorporeal membrane oxygenation for septic shock in an adult with H1N1 influenza | |
| US20080255499A1 (en) | Compositions for Peritoneal Dialysis | |
| WO2019062071A1 (zh) | 脂质体在制备用于清除蛋白结合毒素的药物制剂中的用途 | |
| CN109528762A (zh) | 一种亮氨酸血液透析浓缩液及其制备方法 | |
| CN109512837A (zh) | 一种乳酸血液透析浓缩液及其制备方法 | |
| Awad et al. | Pumpless respiratory assistance using a membrane oxygenator as an artificial placenta: a preliminary study in newborn and preterm lambs | |
| Bargman et al. | Complications other than peritonitis or those related to the catheter and the fate of uremic organ dysfunction in patients receiving peritoneal dialysis | |
| CN205740468U (zh) | 溶氢组件可更换的在线式低压富氢水制备装置 | |
| CN106620914B (zh) | 体外循环人造肺 | |
| CN111603479A (zh) | 血液净化浓缩物 | |
| Zanella et al. | Extracorporeal chloride removal by electrodialysis (Cre-ED): a novel approach to correct acidemia | |
| ITBO20090437A1 (it) | Apparecchiatura per il trattamento del sangue | |
| Burns et al. | 146: Carboxyhemoglobin Associated with Hemolysis as a Marker of Impending Oxygenator Failure in VA ECMO | |
| CN104434959A (zh) | 含有维生素的透析浓缩物 | |
| RU2410080C1 (ru) | Способ получения бикарбонатного диализирующего раствора | |
| Chebrolu et al. | Phosphorus-enriched hemodialysis for the treatment of patients with severe methanol intoxication | |
| JP5371278B2 (ja) | 透析用剤およびその製造方法 | |
| Olszowska et al. | The kinetics of water transperitoneal transport during long-term peritoneal dialysis performed using icodextrin dialysis fluid | |
| RU2438663C1 (ru) | Способ получения гемодиализирующего раствора для бикарбонатного гемодиализа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |
|
| RJ01 | Rejection of invention patent application after publication |